The receipt of this permission paves way for the launch of Olaparib film-coated tablets 100 mg & 150 mg (Lynparza) in India.
AstraZeneca Pharma India is engaged in the business of manufacture, distribution, and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company.
AstraZeneca Pharma tumbled 5.12% to Rs 6,768 after the pharmaceutical firm’s net profit declined 26.62% to Rs 38.43 crore in Q2 FY25 as compared with Rs 52.37 crore posted in Q2 FY24. Revenue from operations jumped 31.16% year on year (YoY) to Rs 408 crore in the quarter ended 30 September 2024.
The counter shed 0.14% to Rs 6,446.55 on the BSE.